logo.jpg
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
December 19, 2023 09:00 ET | Processa Pharmaceuticals, Inc.
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU Interim analysis of the NGC-Cap Phase 1b data shows improved...
rafa-logo.png
Rafarma Pharmaceutical news update
November 30, 2023 09:30 ET | Rafarma Pharmaceuticals Inc.
Russia, Moscow, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA). The Company is pleased to announce that it has completed the restructuring, accounting and balance sheet...
logo.jpg
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference
November 30, 2023 08:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
logo.jpg
Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook
November 29, 2023 08:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next...
logo.jpg
Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas
November 09, 2023 08:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
22157.jpg
China Pharmaceutical Market Landscape and Drugs Pipeline Analysis Report 2023: Business Overview, Clinical Pipeline Insight, Preclinical, Phase-I, Phase-II, Phase-III, Preregistration
November 06, 2023 05:03 ET | Research and Markets
Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "China Pharmaceutical Companies and Drugs Pipeline Insight 2023" drug pipelines has been added to ResearchAndMarkets.com's offering. Chinese...
Global Inhalable Drugs Market
Global Inhalable Drugs Industry Trends and Competitive Landscape 2023-2027: North America Leads, Asia-Pacific Shows Promise
November 01, 2023 08:23 ET | Research and Markets
Dublin, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The "Global Inhalable Drugs Industry Trends and Competitive Landscape 2023-2027" report has been added to ResearchAndMarkets.com's offering.The global...
22157.jpg
Global Oncolytic Virus Therapy Market Trends and Opportunities 2023-2027: Insights for HSV-based Oncolytic Virus, Adenovirus-based Oncolytic Virus, Reovirus, Poxviruses, NDV, and Other Therapy Types
November 01, 2023 08:08 ET | Research and Markets
Dublin, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The "Global Oncolytic Virus Therapy Market 2023" report has been added to ResearchAndMarkets.com's offering. The global oncolytic virus therapy market is...
Global Pediatric Drugs Market
Rising Incidence of Pediatric Diseases and Advances in Research Drive Pediatric Drugs Market Growth
October 25, 2023 09:08 ET | Research and Markets
Dublin, Oct. 25, 2023 (GLOBE NEWSWIRE) -- The "Pediatric Drugs Market by Type, by Route of Administration, Distribution Channel, and by Region - Global Forecast to 2023-2033" report has been added...
Global Multiple Myeloma Drugs Market
Advancements in Healthcare and Targeted Therapies Propel Multiple Myeloma Drugs Market Towards $29.6 Billion by 2028
October 25, 2023 08:23 ET | Research and Markets
Dublin, Oct. 25, 2023 (GLOBE NEWSWIRE) -- The "Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ...